The company - Medical group Fresenius stamps out digital subsidiary Curalie
The medical group Fresenius is continuing its restructuring. Following the sale of its fertility clinics, the DAX-listed company is divesting its subsidiary Curalie. All activities of the software company specializing in health apps will be discontinued at the end of 2023, as the clinic company of the Helios Group announced in Bad Homburg on Friday. Manager Magazin had previously reported on corresponding plans.
According to the Group, the business operations of the parent company Curalie GmbH will be discontinued at the end of 2023, as will the business of almost all subsidiaries. However, the Curalie companies Meditec and Ibs are to be sold.
As a Fresenius spokesperson emphasized, Fresenius is not generally curbing its digital ambitions with the sale of Curalie. Digitalization remains a focus. According to its own statements, Helios intends to concentrate more on the digitalization of its core activities in inpatient and outpatient healthcare, for example through the use of artificial intelligence. With almost 90 clinics, Helios is Germany's largest hospital operator.
The end of Curalie is part of a larger plan with which Fresenius CEO Michael Sen, who has been in office for just over a year, wants to focus the business more strongly and get the highly indebted DAX-listed company back on track. In the spring, Sen announced the separation of "a handful" of parts of the company.
In the meantime, a hospital in Peru and the fertility clinics of the Eugin Group have been sold. According to the latest press reports, around 60 rehabilitation centers and some retirement homes of the Austrian subsidiary Vamed are also up for sale. The project is said to be worth between 600 and 800 million euros.
Press release
Read also:
- A clan member is punished here
- Traffic lawyer warns: Don't talk to the police!
- Will he be convicted as Jutta's murderer after 37 years?
- He also wanted to kill his cousin
Source: www.stern.de
